Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Дата публикации: 28-11-2023 00:00:00

This multicenter, double-blind, randomized trial conducted in nasopharyngeal cancer (NPC)–endemic regions assesses whether toripalimab in combination with gemcitabine-cisplatin as first-line treatment for recurrent or metastatic NPC, compared with gemcitabine-cisplatin alone, will significantly improve progression-free survival and overall survival among chemotherapy-naive patients with recurrent or metastatic NPC.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
2	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
3	PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression	0	15.58	01-07-2026
4	Precision therapy for metastatic prostate cancer improves survival	2	7	20-08-2024
5	Tumor Debulking Plus Chemotherapy for Multiorgan Metastatic Colorectal Cancer	0	8.42	18-08-2026
6	Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer	0	7	22-08-2024
7	Could two drugs be better than one for treating prostate cancer?	5	7	23-01-2024
8	Cancer du pancréas : le daraxonrasib change la donne	0	8.18	05-08-2026
9	Malaga oncologists test ground-breaking drug that sheds light on pancreatic cancer	0	18.7	13-07-2026
10	Un nuevo radiofármaco reduce un 28% el riesgo de progresión o muerte en pacientes con cáncer de próstata metastásico	0	6.27	11-08-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.22. Источник: jamanetwork.com.